EA200100057A1 - Инфекционные клоны вируса ньюкаслской болезни, вакцины и диагностические анализы - Google Patents

Инфекционные клоны вируса ньюкаслской болезни, вакцины и диагностические анализы

Info

Publication number
EA200100057A1
EA200100057A1 EA200100057A EA200100057A EA200100057A1 EA 200100057 A1 EA200100057 A1 EA 200100057A1 EA 200100057 A EA200100057 A EA 200100057A EA 200100057 A EA200100057 A EA 200100057A EA 200100057 A1 EA200100057 A1 EA 200100057A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ndv
vaccines
modify
disease virus
newaslage
Prior art date
Application number
EA200100057A
Other languages
English (en)
Other versions
EA004796B1 (ru
Inventor
Бернардус Петрус Хубертус Петерс
Олав Свен Де Леув
Гуус Кох
Арнауд Леонард Йозеф Гилкенс
Original Assignee
Ид-Лелистад, Инститют Вор Дирхаудерей Эн Диргезондхейд Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8233832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200100057(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ид-Лелистад, Инститют Вор Дирхаудерей Эн Диргезондхейд Б.В. filed Critical Ид-Лелистад, Инститют Вор Дирхаудерей Эн Диргезондхейд Б.В.
Publication of EA200100057A1 publication Critical patent/EA200100057A1/ru
Publication of EA004796B1 publication Critical patent/EA004796B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Настоящее изобретение касается способа получения инфекционного вируса ньюкаслской болезни (NDV) полностью из клонированной полноразмерной кДНК и применения вакцин и диагностических тестов, полученных с помощью упомянутых способов. Этот способ предоставляет возможность модифицировать геном NDV с помощью генетического модифицирования и позволяет вносить мутации, делеции и/или вставки. Данный способ можно использовать для модификации вирулентности NDV, тем самым получая новые ослабленные живые вакцины с улучшенными свойствами. Этот способ можно использовать для модифицирования антигенного спектра NDV, что позволяет получать живые маркерные NDV-вакцины, которые можно отличать от полевых штаммов NDV по серологическим параметрам.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100057A 1998-06-19 1999-06-17 Инфекционные клоны вируса ньюкаслской болезни, вакцины и диагностические анализы EA004796B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98202054A EP0974660A1 (en) 1998-06-19 1998-06-19 Newcastle disease virus infectious clones, vaccines and diagnostic assays
PCT/NL1999/000377 WO1999066045A1 (en) 1998-06-19 1999-06-17 Newcastle disease virus infectious clones, vaccines and diagnostic assays

Publications (2)

Publication Number Publication Date
EA200100057A1 true EA200100057A1 (ru) 2001-08-27
EA004796B1 EA004796B1 (ru) 2004-08-26

Family

ID=8233832

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100057A EA004796B1 (ru) 1998-06-19 1999-06-17 Инфекционные клоны вируса ньюкаслской болезни, вакцины и диагностические анализы

Country Status (28)

Country Link
US (3) US6719979B2 (ru)
EP (2) EP0974660A1 (ru)
JP (3) JP2002518012A (ru)
KR (1) KR20010053000A (ru)
CN (2) CN1314942A (ru)
AR (1) AR020091A1 (ru)
AT (1) ATE367442T1 (ru)
AU (1) AU754844B2 (ru)
BR (1) BR9911383A (ru)
CA (1) CA2334165A1 (ru)
CZ (1) CZ300760B6 (ru)
DE (1) DE69936585T2 (ru)
DK (1) DK1088077T3 (ru)
EA (1) EA004796B1 (ru)
ES (1) ES2291029T3 (ru)
HR (1) HRP20010042B1 (ru)
HU (1) HUP0102429A3 (ru)
ID (1) ID27343A (ru)
IL (2) IL140381A0 (ru)
NO (1) NO329193B1 (ru)
NZ (1) NZ508982A (ru)
PL (1) PL197722B1 (ru)
PT (1) PT1088077E (ru)
SI (1) SI1088077T1 (ru)
TR (1) TR200100350T2 (ru)
UA (1) UA77146C2 (ru)
WO (1) WO1999066045A1 (ru)
ZA (1) ZA200100241B (ru)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US10383936B2 (en) * 1999-05-05 2019-08-20 University Of Maryland, College Park Infectious laryngotracheitis virus (ILTV) vaccine using recombinant newcastle disease virus vector
AU4971500A (en) * 1999-05-05 2000-11-21 University Of Maryland Production of novel newcastle disease virus strains from cdnas and improved liveattenuated newcastle disease vaccines
EP1074614B1 (en) * 1999-07-27 2004-07-07 Akzo Nobel N.V. A recombinant Newcastle disease virus for in ovo vaccination
CA2312626A1 (en) 1999-07-27 2001-01-27 Akzo Nobel N.V. A recombinant newcastle disease virus as an embryo vaccine
DE60139319D1 (en) 2000-06-23 2009-09-03 Intervet Int Bv Us
PT1383795E (pt) 2000-11-02 2007-04-30 Intervet Int Bv Mutante da nucleoproteína do vírus da doença de newcastle recombinante como vacina marcadora
KR100437888B1 (ko) * 2001-07-30 2004-07-03 주식회사 인트론바이오테크놀로지 뉴캐슬병 바이러스 검출용 프라이머 및 상기 프라이머를이용한 뉴캐슬병 바이러스 검출, 병원성 및 유전형 조사방법
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
US7615209B2 (en) 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
ATE307606T1 (de) * 2001-10-04 2005-11-15 Ct Voor Onderzoek In Diergenee Abgeschwächter mutantenstamm eines virus der newcastle-krankheit für eine in ovo impfung und dessen benutzung
US8709442B2 (en) * 2002-02-21 2014-04-29 Icahn School Of Medicine At Mount Sinai Recombinant negative strand virus RNA expression systems and vaccines
TW200502402A (en) * 2002-12-06 2005-01-16 Wyeth Corp Escape mutants of newcastle disease virus as marker vaccines
US20040268442A1 (en) * 2003-05-05 2004-12-30 Dow Agrosciences Llc Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
NZ543348A (en) * 2003-05-05 2008-08-29 Thompson Boyce Plant Res Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
ATE478137T1 (de) 2003-06-20 2010-09-15 Microbix Biosystems Inc Verbesserungen bei der virusproduktion
US7527638B2 (en) 2003-12-16 2009-05-05 Depuy Spine, Inc. Methods and devices for minimally invasive spinal fixation element placement
MY146476A (en) 2004-06-24 2012-08-15 Boehringer Ingelheim Vetmed Method of diagnosing lawsonia intracellularis
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
NZ585895A (en) 2004-11-12 2011-05-27 Bayer Schering Pharma Ag Recombinant newcastle disease virus comprising a transgene encoding a fusion protein comprising a binding domain and a heterologous domain comprising a toxin
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
PL2251034T3 (pl) * 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
AU2007224430A1 (en) * 2006-03-15 2007-09-20 Intervet International B.V. Recombinant Newcastle disease virus expressing H5 hemagglutinin of avian influenza virus
CA2638746C (en) * 2006-03-15 2014-12-02 Intervet International B.V. Recombinant mononegaviral virus vectors
KR100776398B1 (ko) * 2006-03-23 2007-11-28 주식회사 고려비엔피 조류 ｈｎ 단백질의 에피토프 및 상기 변이 에피토프를포함하는 뉴캐슬병 바이러스
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
KR100874256B1 (ko) 2007-02-12 2008-12-16 대한민국 대장균 내독소 단백질 및 뉴캐슬병 바이러스뉴라미니데이즈 에피토프의 융합단백질 및 이의 용도
KR100955502B1 (ko) * 2007-11-30 2010-04-30 대한민국 병원성 뉴캐슬병 바이러스 항체와 특이적으로 반응하는펩타이드 및 그의 용도
EP2085092A1 (en) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
US7794714B2 (en) * 2008-03-14 2010-09-14 The United States Of America As Represented By The Secretary Of Agriculture Newcastle disease virus monoclonal antibodies
US20090258035A1 (en) * 2008-03-21 2009-10-15 The United States Of America, As Represented By The Secretary Of Agriculture Avian virus vaccines and uses thereof
CN102281896A (zh) * 2008-11-19 2011-12-14 阿维-梅克斯实验室公司 重组失活病毒载体疫苗
WO2010091262A1 (en) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Chimeric newcastle disease viruses and uses thereof
CA2771540C (en) * 2009-08-21 2019-01-15 Merial Limited Recombinant avian paramyxovirus vaccine and method for making and using thereof
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
ATE539148T1 (de) 2009-11-30 2012-01-15 United Cancer Res Inst Neuer klon des geflügelpestvirus, herstellung und anwendung bei der medizinischen behandlung von krebs
WO2012151391A2 (en) 2011-05-04 2012-11-08 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
EP2797613B1 (en) 2011-10-27 2019-12-04 Wellstat Ophthalmics Corporation Vectors encoding rod-derived cone viability factor
ES2719409T5 (es) 2011-11-30 2022-12-07 Boehringer Ingelheim Animal Health Usa Inc Vectores recombinantes de Gallid herpesvirus 3 (mdv serotipo 2) que expresan antígenos de patógenos aviares y usos de los mismos
KR101374192B1 (ko) * 2011-12-21 2014-03-14 대한민국 제4형 조류파라믹소바이러스 ｈｎ 단백질 및 이를 포함하는 ｈｉ법 검사용 항원진단액
BR112015021414B1 (pt) 2013-03-14 2020-11-10 Icahn School Of Medicine At Mount Sinai vírus da doença newcastle e seus usos
CN104059942B (zh) * 2013-03-20 2016-12-28 湖北省农业科学院畜牧兽医研究所 新城疫病毒耐热活疫苗载体系统及其应用
US20140341950A1 (en) * 2013-05-15 2014-11-20 University Of Georgia Research Foundation, Inc. Recombinant avian paramyxovirus vaccine and method for making and using thereof
SG11201607130RA (en) 2014-02-27 2016-09-29 Viralytics Ltd Combination method for treatment of cancer
US10780158B2 (en) 2015-11-16 2020-09-22 Georgia State University Research Foundation, Inc. Tunable vaccine platform against pathogens of the paramyxovirus family
JP2019506168A (ja) 2016-02-03 2019-03-07 シージー ディスカバリー インコーポレイテッドＣｇ Ｄｉｓｃｏｖｅｒｙ， Ｉｎｃ． 異種エピトープ及び／又は改変された成熟切断部位を有するインフルエンザヘマグルチニンの組成物
US10063211B2 (en) * 2016-02-03 2018-08-28 Qualcomm Incorporated Compact bypass and decoupling structure for millimeter-wave circuits
US10196616B2 (en) 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof
MX2020008988A (es) * 2018-02-28 2020-09-28 Regeneron Pharma Sistemas y metodos para la identificacion de contaminantes virales.
CA3106170A1 (en) * 2018-07-13 2020-01-16 Icahn School Of Medicine At Mount Sinai Apmv and uses thereof for the treatment of cancer
CN109735552A (zh) * 2019-02-27 2019-05-10 苏州世诺生物技术有限公司 禽新城疫病毒新型基因工程亚单位疫苗
CN110018304A (zh) * 2019-05-15 2019-07-16 河南省农业科学院 一种新城疫抗体阻断检测试纸
CN110240635B (zh) * 2019-06-10 2022-04-22 华中农业大学 检测新城疫病毒抗体的多肽及其elisa检测试剂盒
CN110257562A (zh) * 2019-07-31 2019-09-20 河北农业大学 一种raa-lfd检测鸡传染性喉气管炎病毒的引物和探针组合及其应用
KR102154796B1 (ko) * 2019-10-18 2020-09-22 주식회사 바이오포아 변이 뉴캣슬병 바이러스 및 상기 바이러스를 이용한 조류 백신
CN110938711A (zh) * 2019-12-20 2020-03-31 河北农业大学 一种检测鸡传染性喉气管炎病毒的实时荧光raa引物和探针、试剂盒及其使用方法
CN111334528B (zh) * 2020-03-20 2022-02-18 山东农业大学 水貂肠炎细小病毒全基因组感染性克隆及其构建方法和应用
CN112048484A (zh) * 2020-07-27 2020-12-08 华南农业大学 一株表达传染性法氏囊强毒株vp2蛋白的基因ⅶ型新城疫重组病毒和疫苗
CN114214338B (zh) * 2021-08-26 2023-02-03 扬州大学 猪源piv5全长感染性克隆及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
ES2210273T5 (es) 1994-07-18 2010-03-29 Conzelmann, Karl-Klaus, Prof. Dr. Virus con arn de cadena negativa no segmentado recombinante infeccioso.
WO1996040880A1 (en) * 1995-06-07 1996-12-19 Syntro Corporation Recombinant fowlpox viruses and uses thereof
DE69510207T3 (de) * 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
EP0839912A1 (en) * 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines

Also Published As

Publication number Publication date
JP2006141398A (ja) 2006-06-08
DE69936585D1 (de) 2007-08-30
IL140381A0 (en) 2002-02-10
EP1088077B1 (en) 2007-07-18
BR9911383A (pt) 2001-03-13
NO329193B1 (no) 2010-09-13
PL348300A1 (en) 2002-05-20
EP0974660A1 (en) 2000-01-26
US7547442B2 (en) 2009-06-16
CN101275142A (zh) 2008-10-01
EP1088077A1 (en) 2001-04-04
DK1088077T3 (da) 2007-11-12
EP1088077B2 (en) 2012-03-21
PT1088077E (pt) 2007-10-29
CZ300760B6 (cs) 2009-08-05
CN1314942A (zh) 2001-09-26
IL140381A (en) 2008-06-05
US20040235134A1 (en) 2004-11-25
US6719979B2 (en) 2004-04-13
US20030087417A1 (en) 2003-05-08
HRP20010042A2 (en) 2001-12-31
CZ20004707A3 (en) 2001-05-16
ZA200100241B (en) 2002-06-26
AU4399199A (en) 2000-01-05
UA77146C2 (en) 2006-11-15
ES2291029T3 (es) 2008-02-16
HUP0102429A3 (en) 2003-12-29
NZ508982A (en) 2003-07-25
EA004796B1 (ru) 2004-08-26
AR020091A1 (es) 2002-04-10
ID27343A (id) 2001-04-05
US7332169B2 (en) 2008-02-19
TR200100350T2 (tr) 2001-06-21
PL197722B1 (pl) 2008-04-30
SI1088077T1 (sl) 2008-02-29
NO20006406L (no) 2001-02-19
ATE367442T1 (de) 2007-08-15
WO1999066045A1 (en) 1999-12-23
US20040234552A1 (en) 2004-11-25
NO20006406D0 (no) 2000-12-15
HUP0102429A2 (hu) 2001-10-28
JP2009261387A (ja) 2009-11-12
DE69936585T2 (de) 2008-04-30
JP2002518012A (ja) 2002-06-25
KR20010053000A (ko) 2001-06-25
AU754844B2 (en) 2002-11-28
CA2334165A1 (en) 1999-12-23
HRP20010042B1 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
EA200100057A1 (ru) Инфекционные клоны вируса ньюкаслской болезни, вакцины и диагностические анализы
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
DE60224843D1 (de) Herstellung von viren, virusisolaten, und impfstoffen
Ma et al. Genetic diversity of avian infectious bronchitis coronavirus in recent years in China
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
Feng et al. Development and efficacy of a novel live-attenuated QX-like nephropathogenic infectious bronchitis virus vaccine in China
ATE491720T1 (de) Impfstoff gegen pasteurella multocida
ES2038689T3 (es) Procedimiento de cultivo del virus de la rinotraqueitis infecciosa de la pava, y vacuna preparada a partir del virus asi obtenido.
DK1383795T3 (da) Rekombinant nucleoproteinmutant fra Newcastle disease-virus som markörvaccine
Abdel-Alim et al. Immunogenicity and antigenicity of very virulent strains of infectious bursal disease viruses
EP1324768A2 (en) Vaccines for proliferative ileitis
AU2001293151A1 (en) Improved Vaccines for Proliferative Ileitis and Methods of Making and Using the Same
CN103555680B (zh) 一种具有免疫原性的prrsv病毒样颗粒及其制备与应用
US6231868B1 (en) Method for generating nonpathogenic infections birnavirus from synthetic RNA transcripts
Hidalgo et al. Isolation of infectious bronchitis virus from broiler chickens in Chile
DE602004015418D1 (de) Rekombinantes mva und verfahren zur erzeugung davon
DE60236806D1 (de) Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
RU2018131243A (ru) Композиции гемагглютинина гриппа с гетерологичными эпитопами и/или измененными сайтами расщепления при созревании
KR20230022206A (ko) 코로나바이러스 질환에 대응하는 재조합적 변형된 우두증 바이러스 앙카라 (mva) 백신
DE68920345D1 (de) Lebendes Kombinationsvakzin.
Boroomand et al. Molecular detection and phylogenetic properties of isolated infectious bronchitis viruses from broilers in Ahvaz, southwest Iran, based on partial sequences of spike gene
RU2078817C1 (ru) Аттенурованный холодоадаптированный штамм вируса гриппа, используемый для получения живой интраназальной гриппозной вакцины
US8728484B2 (en) Vaccine for runting-stunting syndrome
WO2003011335A3 (de) Polyvalente vakzine gegen durch papillomaviren verursachte erkrankungen, verfahren zu deren herstellung und deren verwendung
KR20200037570A (ko) 돼지 생식기 호흡기 증후군 바이러스의 키메릭 변이주

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU